<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="235">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 16, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343092</url>
  </required_header>
  <id_info>
    <org_study_id>PRO20040001</org_study_id>
    <nct_id>NCT04343092</nct_id>
  </id_info>
  <brief_title>Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients</brief_title>
  <official_title>Adjuvant Use of Ivermectin To Hydroxychloroquine in Patients With Covid19: A Novel Double Blind Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Baghdad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Baghdad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the efficacy and safety of adjuvant use of Ivermectin in covid19 patients with
      pneumonia using Ivermectin with hydroxychloroquine compared to HCQ
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing the efficacy and safety of adjuvant use of Ivermectin in covid19 patients with
      pneumonia using Ivermectin 0.2mg/kg (12 mg adult dose ) single dose at once repeated after 1
      week combined with hydroxychloroquine 400mg daily compared to HCQ 400 daily plus placebo
      single one dose repeated after 1 week.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 8, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cured patients</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of patients cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for covid19 (PCR) in addtion to Chest xary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Adverse events are assessed by Complete blood count (CBC), Liver function tests (ALT, AST),Renal function tests (blood urea, serum creatinine) and Fasting blood sugar test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Ivermectin + Hydroxychloroquin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+ Hydroxychloroquin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ( lactose ) 12mg/weekly + Hydroxychloroquine 400mg/daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectine</intervention_name>
    <description>Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly</description>
    <arm_group_label>Ivermectin + Hydroxychloroquin</arm_group_label>
    <other_name>Ivermectin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate</intervention_name>
    <description>Hydroxychloroquine Sulfate 400mg/daily</description>
    <arm_group_label>Ivermectin + Hydroxychloroquin</arm_group_label>
    <arm_group_label>Placebo+ Hydroxychloroquin</arm_group_label>
    <other_name>Hydroxychloroquin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>(0.2 mg /kg=12 mg ) lactose single dose at once/ weekly</description>
    <arm_group_label>Placebo+ Hydroxychloroquin</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -1. Patients with age above 18 years and any gender with definite Dx of covid19 and
        pneumonia in the ward according to the clinical, laboratory, and imaging criteria.

        2. Understands and agrees to comply with planned study procedures.

        Exclusion Criteria:

          1. Patients with hypersensitivity or severe adverse effects to Ivermectin

          2. Renal impairment

          3. Hepatic impairment.

          4. Pregnancy or a desire to become pregnant (drug considered pregnancy category c)

          5. Breast feeding.

          6. Patient with covid 19 positive and mild no pneumonia

          7. Children under the age of five or those who weigh less than 15 kilograms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Baghdad</investigator_affiliation>
    <investigator_full_name>Faiq Gorial</investigator_full_name>
    <investigator_title>Professor and consultant rheumatologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

